Investor Overview

Webcast ImageWebcast
Q4 2018 AtriCure, Inc. Earnings Conference Call (Replay)
02/28/19 at 4:30 p.m. ET
Webcast ImageWebcast
AtriCure, Inc. at 37th Annual J.P. Morgan Healthcare Conference (Replay)
01/07/19 at 12:00 p.m. PT

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$28.33 - 0.712.44%200,615
Previous CloseToday's OpenIntraday HighIntraday Low
$29.04$29.04$29.17$27.86
Exchange: NASDAQ (US Dollar)
03/18/19 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
02/28/19
Download Documentation Q4 2018 Earnings Call Transcript
01/07/19
Download Documentation Investor Presentation
11/01/18
Download Documentation Q3 2018 Earnings Call Transcript

All Recent News

DateTitle 
02/28/19AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) ... 
Printer Friendly Version
02/19/19AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio--(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medic... 
Printer Friendly Version
02/12/19AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block MASON, Ohio--(BUSINESS WIRE)--Feb. 12, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedic... 
Printer Friendly Version
02/05/19AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio--(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
02/28/19AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) ... 
Printer Friendly Version
02/19/19AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio--(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medic... 
Printer Friendly Version
02/12/19AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block MASON, Ohio--(BUSINESS WIRE)--Feb. 12, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedic... 
Printer Friendly Version
02/05/19AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio--(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
  More International News >>

Company Calendar

There are currently no events scheduled.
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.